requip tablet 2 mg
glaxosmithkline pte ltd - ropinirole hcl eqv ropinirole - tablet, film coated - 2 mg - ropinirole hcl eqv ropinirole 2 mg
appese 0.25 ropinirole (as hydrochloride) 0.25 mg tablet blister pack
arrotex pharmaceuticals pty ltd - ropinirole hydrochloride, quantity: 0.285 mg (equivalent: ropinirole, qty 0.25 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - treatment of primary restless legs syndrome, including the reduction of associated periodic limb movement and episodes of nocturnal arousal.
repreve ropinirole (as hydrochloride) 1 mg tablet blister pack
arrotex pharmaceuticals pty ltd - ropinirole hydrochloride, quantity: 1.14 mg (equivalent: ropinirole, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - treatment of primary restless legs syndrome, including the reduction of associated periodic limb movement and episodes of nocturnal arousal.
amisulpride 400mg tablets
sigma pharmaceuticals plc - amisulpride - oral tablet - 400mg
serdolect 4mg tablets
imported (denmark) - sertindole - oral tablet - 4mg
serdolect 16mg tablets
imported (denmark) - sertindole - oral tablet - 16mg
serdolect 20mg tablets
imported (denmark) - sertindole - oral tablet - 20mg
ropinirole hydrochloride tablet, film coated
zhejiang huahai pharmaceutical co., ltd. - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole hydrochloride 0.25 mg - ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson’s disease. the effectiveness of ropinirole hydrochloride was demonstrated in randomized, controlled trials in patients with early parkinson’s disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may frequently be associ
amisulpride 200mg tablets
sigma pharmaceuticals plc - amisulpride - oral tablet - 200mg
serdolect 4 mg
lundbeck israel ltd. - sertindole - film coated tablets - sertindole 4 mg - sertindole - sertindole - for the treatment of schizophrenia. due to cardiovascular safety concerns serntidole should only be used for patients intolerant to at least one other anti-psychotic agent. sertindole should not be used in emergency situations for urgent relief of symptoms in acutely disturbed patients.